Insmed
Clinical trials sponsored by Insmed, explained in plain language.
A biopharmaceutical company focused on serious rare diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New inhaled powder shows promise for Long-Term PAH control Results expected Dec 2026 (estimated) May already have reported ↗
- Liver health may change how body handles inhaled lung drug Results expected Feb 2027 (estimated) May already have reported ↗
- Could a new oral drug pass its first safety hurdle? Results expected Mar 2027 (estimated)
-
Inhaled therapy aims to slow the march of progressive pulmonary fibrosis
Disease control Not yet recruitingThis phase 3 trial tests an inhaled drug called treprostinil palmitil in adults with progressive pulmonary fibrosis, a condition where lung scarring worsens over time despite standard care. Participants inhale the drug or a placebo once daily for 52 weeks. Researchers measure whe…
Phase 3 • Sponsor: Insmed Incorporated • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Could a new oral drug pass its first safety hurdle?
Knowledge-focused Not yet recruitingThis early-stage trial is testing an investigational drug called INS1033, given as an oral solution, to see if it is safe and well-tolerated in healthy adults. Participants receive either single or multiple rising doses of the drug or a placebo, and researchers monitor for side e…
Phase 1 • Sponsor: Insmed Incorporated • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC